SR 16832
CAS No. 2088135-12-8
SR 16832( SR-16832 | SR16832 )
Catalog No. M27795 CAS No. 2088135-12-8
SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 36 | In Stock |
|
| 10MG | 56 | In Stock |
|
| 25MG | 113 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 295 | In Stock |
|
| 200MG | 427 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSR 16832
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
-
DescriptionSR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
-
In Vitro——
-
In Vivo——
-
SynonymsSR-16832 | SR16832
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorP2X7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2088135-12-8
-
Formula Weight357.75
-
Molecular FormulaC17H12ClN3O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (698.81 mM)
-
SMILESCOc1ccc2nccc(NC(=O)c3cc(ccc3Cl)[N+]([O-])=O)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Stock TC, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
molnova catalog
related products
-
GW590735
GW590735 is an effective and selective PPARα agonist with an EC50 of 4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW590735 can be used in dyslipidemia studies.
-
Lenabasum
A synthetic nonpsychoactive cannabinoid acid with potent analgesic and anti-inflammatory activity in vivo, binds directly and selectively to PPARγ.
-
Muraglitazar
Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia.
Cart
sales@molnova.com